Nexvet Biopharma

Nexvet (US:NVET) is a global clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel biologic therapies , including “100% species-specific” products derived from their PETization™ technology.

PETization™ is designed to rapidly create monoclonal antibodies (“mAbs”) that are recognized as “self” by a patient’s immune system, a property we refer to as 100% species-specificity.

To learn more, visit

Nexvets PETization Technology